Business Context and Reporting Period
This Form 6-K filing by Sanofi-Synthelabo (now Sanofi-Aventis) covers the period ending August 20, 2004. The report announces the successful completion of the acquisition of Aventis, resulting in the creation of Sanofi-Aventis, which is now the world's third-largest pharmaceutical company and the largest in Europe.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures for the reporting period. The document focuses exclusively on the corporate transaction and regulatory disclosures.
Material Changes
- Acquisition Completion: The settlement of the offer for Aventis occurred on August 20, 2004.
- Ownership Stake: Sanofi-Synthelabo now controls Aventis with 95.47% of its share capital.
- Corporate Name Change: The registrant has officially changed its name from Sanofi-Synthelabo to Sanofi-Aventis.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future earnings or operational performance. The primary focus is on the legal and procedural aspects of the merger.
Risks and Contingencies: The document highlights regulatory restrictions on the distribution of the communication and the sale of securities in various jurisdictions (including the U.S., Germany, Italy, and Japan) prior to proper registration or qualification. It emphasizes that the press release does not constitute an offer to purchase or sell securities in jurisdictions where such actions would be unlawful.
Investor Verification Checklist
- Verify the final ownership percentage of Aventis held by Sanofi-Aventis (stated as 95.47%).
- Confirm the official name change to Sanofi-Aventis in subsequent filings.
- Review the Registration Statement on Form F-4 (File No. 333-112314) for detailed terms of the revised offer.
- Check for any subsequent filings regarding the integration of Aventis operations and the resulting consolidated financial statements.